Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss severity is linked to depression, not anxiety, in Filipino men, with older, less educated men with more hair loss at higher risk.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

Hair loss can cause low self-esteem, anxiety, and depression in men.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.

The document concludes that alopecia areata is an autoimmune disease without a definitive cure, but treatments like corticosteroids are commonly used.

Baricitinib is effective and safe for treating severe alopecia areata.

Women with PCOS often have mood disorders and a lower quality of life, and treatment should focus on both physical and mental health.

Women with PCOS have a higher risk of diabetes, heart problems, certain cancers, and mental health issues, but early treatment can help manage these risks.

Stress and emotional factors can worsen skin conditions by affecting the immune system.

Alopecia areata is an autoimmune hair loss condition treated with corticosteroids, and histologic confirmation is the best diagnosis method.

Women with scarring alopecia have a lower quality of life and more anxiety and depression than those with non-scarring alopecia.

The conclusion is that understanding and addressing the psychological effects of alopecia areata is important for effective treatment.

Wigs significantly improve the well-being of people with severe hair loss.

Hair camouflage offers various options for hair loss, helping reduce psychological impact.

JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.

Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.

Hair loss in Chinese college students leads to various psychological issues, so treatment should address both hair loss and mental health.

Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.

Lupus patients' body image issues significantly affect their mental health and need more support.

More hair loss leads to higher risk of psychosexual disorders, especially in women.

Most people in Turkey start getting gray hair around 33 years old, with factors like age, education, hair loss, skin type, family history, and anxiety playing a role.

Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.

People with alopecia areata are more likely to have anxiety and depression and a lower quality of life.

Women with Polycystic Ovary Syndrome (PCOS) often have higher levels of anxiety and depression, especially if they live in rural areas, have less education, don't have children, are over 30, or are obese.

Dermatological diseases affect women's work performance more than men's.

Hair loss lowers young men's self-esteem, increasing social anxiety and affecting daily life.

The document concludes that alopecia areata is an unpredictable autoimmune hair loss condition with no cure, but various treatments exist that require personalized approaches.

Personality traits significantly affect the onset, progression, and psychological impact of alopecia areata.

Skin diseases can cause psychological issues, and better integration of dermatology and psychiatry is needed to improve patient care.